After hours: January 8 at 5:16:11 PM EST Loading Chart for BLCO ...

Twenty-one months into his second tenure as CEO of Bausch + Lomb, serial dealmaker Brent Saunders has so far come up empty in his latest attempt to sell the company. But it hasn’t been for lack ...

Bausch & Lomb (NYSE:BLCO) rose 1.3% after confirming a sales process for the eyecare company. The maker of contact lenses commented on the sales process following a request from the Canadian ...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, issued the following ...

VAUGHAN, Ontario, December 12, 2024--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better ...

Bausch + Lomb announced today that, in response to a request from regulatory authorities, it authorized the exploration of a potential sale. The Vaughan, Ontario-based eye care company received a ...

Interested in blogging for timesofindia.com? We will be happy to have you on board as a blogger, if you have the knack for writing. Just drop in a mail at [email protected] with a brief ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Dec 12 (Reuters) - Bausch + Lomb (BLCO.TO), opens new tab is exploring a potential sale among other options, it said on Thursday, in a move that would help Canadian parent Bausch Health (BHC.TO ...

Bausch + Lomb Corp. says it’s exploring several options including a potential sale of the company. The company made the comment after a request by the Canadian Investment Regulatory Organization.

Bausch + Lomb said it authorized management and advisers to explore a potential sale of the eye health company after shares dropped over reports of faltering deal talks with a group of private ...

Shares in ophthalmology specialist Bausch + Lomb (B+L) have lost almost 10% of their value on a report that a joint takeover bid for the group is in trouble. The Financial Times has said that ...